ISRCTN99675218CompletedNot Applicable
Effect of treatment with low-dose hydrocortisone on cirrhotic patients presenting with septic shock to the intensive care unit
King Abdul Aziz City For Science and Technology (Saudi Arabia)0 sites150 target enrollmentStarted: September 8, 2005Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Cirrhotic patients admitted to the Intensive Care Unit with septic shock
Exclusion Criteria
- •1. Pure hypovolemia
- •2. Hemorrhagic shock
- •3. Known adrenal insufficiency
- •4. Prior steroid use
- •5. Do not resuscitate (DNR) order
- •6. Patients in terminal condition
- •7. Contraindication to steroids
- •8. Refused consent
- •9. Post-cardiac arrest
- •10. Patient unexpected to survive 24 hours
Investigators
Similar Trials
Recruiting
Phase 2
The effect of low-dose hydrocortisone on neonatal respiratory status under mechanical ventilatiorespiratory status under mechanical ventilation.Other chronic respiratory diseases originating in the perinatal periodP27.8IRCT20200721048155N1Mashhad University of Medical Sciences30
Recruiting
Phase 3
Evaluation of the effects of hydrocortisone on hemodynamic changes in patients under general anesthesiaPatients for elective surgery for upper limb fractures.Fracture of upper limb, level unspecifiedIRCT20170108031818N2Gorgan University of Medical Sciences48
Not yet recruiting
Phase 3
Effect of treatment with (Hydrocortisone+ Ascorbic acid+ Neurobion)on multiple trauma patientsIRCT20201116049410N1Esfahan University of Medical Sciences70
Completed
Not Applicable
Evaluation effect of Hydrocortisone on amylase level of patients underwent Endoscopic retrograde cholangiopancreatographyAcute pancreatitis.Disease of pancreas, unspecifiedIRCT201410236388N6Vice chancellor of Tabriz University of Medical Sciences90
Completed
Phase 2
Evaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19IRCT20120215009014N354Hamedan University of Medical Sciences81